Skip to main content
NRSN
NASDAQ Life Sciences

NeuroSense Reports Constructive Health Canada Meeting for PrimeC ALS Drug

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.796
Mkt Cap
$26.516M
52W Low
$0.63
52W High
$2.6
52W Position info
26% above low
Off High info
69% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

NRSN sits 26% above its 52-week low of $0.63.

Summary

NeuroSense Therapeutics held a constructive meeting with Health Canada regarding the regulatory pathway for its lead ALS drug, PrimeC, with an official response on the New Drug Submission expected in Q3 2026.


Key Events · Product Development and Regulatory · NRSN

  • Constructive Health Canada Meeting

    NeuroSense Therapeutics held a productive meeting with Health Canada to discuss the regulatory pathway for PrimeC, its lead drug candidate for ALS.

  • New Drug Submission (NDS) Strategy Discussed

    The meeting focused on the company's proposed NDS strategy and the clinical, biomarker, and long-term outcome data supporting a potential NDS filing.

  • Official Response Expected Q3 2026

    Health Canada is expected to provide an official response regarding the regulatory process in the third quarter of this year.


Analysis · NRSN · Life Sciences

This filing details a positive regulatory meeting with Health Canada for PrimeC, the company's lead drug candidate for ALS. The discussions focused on the New Drug Submission (NDS) strategy and supporting data, with an official response expected in Q3 2026. This progress is crucial for NeuroSense, especially given its recent 'going concern' warning, as it advances the potential market entry of its key asset.

How filings like this one have moved

In the 30 days to Sep 13, 2026, 35.3% of the 1324 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NRSN was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.5M. The 52-week trading range was $0.63 to $2.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NRSN - Latest Insights

NRSN
Sep 09, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.393
Real-time Price: $0.3399 info
Change: Reverse Stock Split info
Market Cap: $13.112M info
NRSN
Aug 27, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.4389
Real-time Price: $0.3399 info
Change: Reverse Stock Split info
Market Cap: $13.112M info
NRSN
Aug 13, 2026, 10:55 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.4527
Real-time Price: $0.3399 info
Change: Reverse Stock Split info
Market Cap: $13.112M info
NRSN
Aug 06, 2026, 11:55 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.5498
Real-time Price: $0.3399 info
Change: Reverse Stock Split info
Market Cap: $13.112M info
NRSN
Jul 31, 2026, 4:16 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.4652
Real-time Price: $0.3399 info
Change: Reverse Stock Split info
Market Cap: $13.112M info